Amneal Pharmaceuticals - AMRX Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amneal Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AMRX shares.
View AMRX analyst ratings or view top-rated stocks.

3 equities research analysts have issued 12 month price objectives for Amneal Pharmaceuticals' stock. Their AMRX share price forecasts range from $3.00 to $4.00. On average, they anticipate the company's stock price to reach $3.67 in the next year. This suggests a possible upside of 156.4% from the stock's current price.
View analysts price targets for AMRX or view top-rated stocks among Wall Street analysts.

Amneal Pharmaceuticals' stock was trading at $1.99 at the beginning of 2023. Since then, AMRX shares have decreased by 28.1% and is now trading at $1.43.
View the best growth stocks for 2023 here.

Amneal Pharmaceuticals saw a decrease in short interest during the month of February. As of February 28th, there was short interest totaling 7,120,000 shares, a decrease of 11.7% from the February 13th total of 8,060,000 shares. Based on an average daily trading volume, of 1,290,000 shares, the short-interest ratio is presently 5.5 days. Currently, 7.2% of the shares of the stock are sold short.
View Amneal Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our AMRX earnings forecast.

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) posted its earnings results on Thursday, March, 2nd. The company reported $0.21 earnings per share for the quarter, topping analysts' consensus estimates of $0.19 by $0.02. The business earned $609.80 million during the quarter, compared to analysts' expectations of $579.93 million. Amneal Pharmaceuticals had a positive trailing twelve-month return on equity of 76.11% and a negative net margin of 5.88%. The business's quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter last year, the business earned $0.16 earnings per share.

Amneal Pharmaceuticals updated its FY23 earnings guidance on Thursday, March, 2nd. The company provided EPS guidance of $0.40-0.50 for the period, compared to the consensus EPS estimate of $0.77. The company issued revenue guidance of $2.25-2.35 billion, compared to the consensus revenue estimate of $2.31 billion.

23 employees have rated Amneal Pharmaceuticals Chief Executive Officer Chirag and Chintu Patel on Glassdoor.com. Chirag and Chintu Patel has an approval rating of 91% among the company's employees. This puts Chirag and Chintu Patel in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amneal Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Teva Pharmaceutical Industries (TEVA), Cisco Systems (CSCO), Micron Technology (MU), General Electric (GE), OPKO Health (OPK), Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV) and Bausch Health Companies (BHC).

Amneal Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "AMRX."

Amneal Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (1.65%), Morgan Stanley (1.39%), Norges Bank (0.89%), AQR Capital Management LLC (0.70%), Geode Capital Management LLC (0.60%) and Allspring Global Investments Holdings LLC (0.52%). Insiders that own company stock include Chirag K Patel, Gautam Patel, Jeffrey P George, John Kiely, Joseph Todisco, Nikita Shah and Tpg Gp A, Llc.
View institutional ownership trends.

Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMRX stock can currently be purchased for approximately $1.43.

Amneal Pharmaceuticals (NYSE:AMRX) has a market capitalization of $434.18 million and generates $2.21 billion in revenue each year. The company earns $-129,990,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis.

The company employs 7,600 workers across the globe.

Amneal Pharmaceuticals' mailing address is 400 CROSSING BOULEVARD, BRIDGEWATER NJ, 08807. The official website for the company is www.amneal.com. The company can be reached via phone at (908) 947-3120, via email at invest@amneal.com, or via fax at 908-947-3146.